NAD+ is a coenzyme every cell uses to move electrons through metabolism and to fuel DNA repair enzymes. Tissue levels fall with age in animals and in human tissue samples. That observation is the entire commercial basis for the NAD+ supplement category, which is now built around two molecules: nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN).
The Verdict
What separates the two molecules
NR and NMN are one phosphate group apart. NMN is NR with a phosphate attached, and both sit one or two steps from NAD+ itself in the salvage pathway.
That small difference matters for how each one gets into a cell. NR crosses the cell membrane intact and is phosphorylated to NMN once inside. NMN carries a charged phosphate group, which makes membrane crossing harder, so most of it is stripped back to NR at the cell surface and rebuilt inside. A dedicated NMN transporter called Slc12a8 was reported in mouse intestine in 2019, but its relevance in human tissue is still argued over.
The practical consequence is that both compounds converge on the same pathway. Marketing that presents NMN as "one step closer to NAD+" is describing a diagram rather than a measured advantage in people.
| NR (nicotinamide riboside) | NMN (nicotinamide mononucleotide) | |
|---|---|---|
| Full name | Nicotinamide riboside | Nicotinamide mononucleotide |
| Molecule | A ribose sugar joined to nicotinamide. No phosphate group. | The same molecule with a phosphate group attached. |
| Route into the cell | Enters intact, then gets phosphorylated to NMN inside the cell. | Generally dephosphorylated to NR at the cell surface, then re-phosphorylated inside. |
| US regulatory status | Marketed under new dietary ingredient notifications; the Niagen form also has GRAS notices on file. | Excluded by FDA in 2022, then reinstated on 29 September 2025. Each supplier still needs its own notification. |
| Human trial doses studied | 250–2,000 mg/day | 250–900 mg/day |
| Does blood NAD+ rise? | Yes, dose-dependently, across multiple trials. | Yes, in the trials published so far. |
| Do functional outcomes improve? | Inconsistent. Some signals, several null results. | Inconsistent. Fewer and smaller trials. |
The regulatory split, and why it changed in 2025
This is where the two ingredients genuinely diverged, and it is the part most product pages skip.
In late 2022 the US Food and Drug Administration told ingredient suppliers that NMN could not be sold as a dietary supplement. The reasoning was procedural rather than safety-based: NMN had been authorised for investigation as a new drug, and an ingredient studied as a drug first is excluded from the supplement definition. Major retailers delisted NMN products over the following year.
That position was reversed. Responding to a citizen petition, FDA concluded on 29 September 2025 that NMN is not excluded from the dietary supplement definition, after evidence showed NMN had been marketed as a dietary supplement before it was authorised for drug investigation. Confirmation letters went to ingredient suppliers in December 2025. The Natural Products Association, which had sued over the original decision, documented the sequence and the docket references.
One detail survives the reversal. NMN is still a new dietary ingredient, so the notification requirement is per supplier, not blanket coverage for the whole category. A brand that changed material sources during the exclusion may not be covered by anyone's notification.
NR never went through this. The licensed Niagen form has been marketed under accepted new dietary ingredient notifications and also carries generally-recognised-as-safe notices on file with FDA. For a buyer, the regulatory history is one of the few hard differences available.
What the human trials actually measured
Nearly every trial in this category measured the same primary endpoint: did blood NAD+ go up? The answer is consistently yes. The harder question is whether anything downstream followed.
| Trial | Design | What rose | What it did not show |
|---|---|---|---|
| Trammell 2016 (NR) | 12 adults, single ascending dose | Whole-blood NAD+ rose up to 2.7-fold | Established that oral NR reaches the blood at all. |
| Martens 2018 (NR) | 24 adults aged 55–79 completed, 6 weeks | Whole-blood NAD+ rose about 60%; most vascular measures unchanged | The whole-group systolic drop did not reach significance. The larger drop was in a 13-person subgroup that started elevated. |
| Elhassan 2019 (NR) | 12 older men, 3 weeks | Muscle NAD+ metabolites rose | Mitochondrial bioenergetics did not change. The clearest example of the gap between the marker and the outcome. |
| Yoshino 2021 (NMN) | 25 postmenopausal women with prediabetes, 10 weeks | Muscle insulin sensitivity improved | Body weight, blood pressure and liver fat did not change. A single small trial. |
| Igarashi 2022 (NMN) | 42 older men randomised, 20 analysed, 12 weeks | Blood NAD+ rose; gait speed and left-grip strength improved nominally | A supplier error gave 22 participants the wrong material. Industry-funded, and the surviving sample is small. |
Read the third row twice. Elhassan and colleagues gave older men NR for three weeks, confirmed that NAD+ metabolites in skeletal muscle increased, and found no accompanying change in mitochondrial bioenergetics. The supplement did what it claimed to the marker and not to the function the marker is supposed to represent.
This is the recurring pattern across the category, and it is the reason we rank NAD+ precursors below zone 2 training and protein adequacy in the evidence tiers on our supplements hub. A marker that moves is not a benefit that arrived.
Where to read the trials yourself
- Trammell et al. 2016, Nature Communications: first demonstration that oral NR raises human blood NAD+.
- Martens et al. 2018, Nature Communications: NR in adults aged 55–79.
- Elhassan et al. 2019, Cell Reports: muscle NAD+ rose, bioenergetics did not.
- Yoshino et al. 2021, Science: NMN and muscle insulin sensitivity.
- Igarashi et al. 2022, npj Aging: read the participant-flow section before the abstract.
How the category compares to other longevity supplements
| Supplement | Marker you can test | Human outcome evidence | Where it sits |
|---|---|---|---|
| Vitamin D | 25-OH vitamin D, widely available | Strong for correcting deficiency, weak for supplementing the already-replete | Test first, then decide |
| Omega-3 | Omega-3 index (RBC EPA + DHA) | Moderate, dose-dependent, measurable | Test first, then decide |
| Creatine | No direct assay; strength and lean mass are the readouts | Strong for muscle, growing for cognition | Reasonable without testing |
| NAD+ precursors (NR, NMN) | None available clinically | NAD+ rises reliably; function does not follow consistently | Speculative purchase |
| Senolytics | No validated senescence assay | Early trials, mostly in disease populations | Speculative purchase |
On the evidence as it stands, NR is the better-supported purchase: more published human trials, a longer regulatory record, and a licensed form that matches the material used in those trials. NMN is the thinner case, and anyone buying it should confirm their supplier's notification status after the 2025 reinstatement. The stronger argument, though, is against the category. The same monthly spend on a panel that returns a number you can act on buys more information than either compound currently does.
What to check on a label before buying
| Check | Why it matters |
|---|---|
| Which precursor, and how much per serving | Some products list a proprietary blend and never state the NR or NMN dose. The trial range is meaningless if you cannot locate your dose inside it. |
| Whether the NR is a licensed form | Niagen is the form used in most published NR trials. A generic NR is not automatically the same material. |
| Whether the supplier holds a notification | After the 2025 reinstatement, NMN is lawful again, but the notification requirement is per-supplier. A brand that switched sources may not be covered. |
| Third-party purity testing | Content testing in this category has found products deviating from their labelled amounts, and neither compound is easy to verify by eye. A certificate of analysis tied to the specific lot is the practical check. |
| Added ingredients doing the marketing | Pterostilbene, resveratrol and trimethylglycine are frequently added. They are separate compounds with separate evidence, and they are not what the NAD+ trials tested. |
Questions worth raising with a clinician
- Any cancer history or active surveillance. NAD+ metabolism is active in tumour cells, and the direction of effect from supplementation is unresolved. This belongs with an oncologist rather than a supplement retailer.
- Existing prescriptions, particularly for blood pressure. The one repeated signal in the NR literature is a blood pressure effect in people who started elevated.
- Kidney or liver impairment, since the trials enrolled adults without organ dysfunction and cannot speak to those groups.
- Whether a cheaper unresolved deficiency is present. Low vitamin D, low ferritin or an omega-3 index under 4% are correctable, measurable and usually cost less to fix.
NAD+ Infusions Cost More And Carry Less Evidence Than Either Capsule
Intravenous NAD+ is sold by longevity and wellness clinics as the direct version of what NMN and NR do indirectly, and it has no randomised human trial behind it for any outcome. A single infusion typically runs several hundred dollars and takes two to four hours, because pushing it faster produces flushing, nausea and chest tightness that patients consistently report.
The mechanistic argument for infusion is that it bypasses the gut. The counter-argument is that circulating NAD+ is broken down to nicotinamide before it enters most cells, so what reaches the tissue may not differ much from what an oral precursor delivers. Nobody has run the head-to-head study that would settle it, and no trial has measured tissue NAD+ after an infusion in humans.
That leaves the comparison lopsided in a specific way. Oral NMN and NR have small trials showing blood NAD+ rises, which is a weak evidence base. Intravenous NAD+ has case series and clinic marketing, which is weaker still, at roughly twenty times the cost per session. Our page on longevity clinic costs covers where these infusions sit in a typical clinic price list, and our pages on NMN dosage and NMN side effects cover what the oral trials used and reported.
Frequently Asked Questions
Is NMN or NR better for raising NAD+?
Both raise blood NAD+ in human trials, and no head-to-head trial has established that one is better at the doses people actually take. NR has more published human data and a longer regulatory track record. NMN has fewer trials, though the ones published report similar increases in blood NAD+. The more useful distinction right now is regulatory and manufacturing quality rather than biochemistry.
Is NMN legal to sell in the United States?
Yes, as of 29 September 2025. FDA had concluded in 2022 that NMN was excluded from the dietary supplement definition because it had been authorised for investigation as a drug. Following a citizen petition and litigation, FDA reversed that conclusion and issued confirmation letters to ingredient suppliers in December 2025. NMN remains a new dietary ingredient, so each supplier must still hold its own notification.
Does raising NAD+ mean you are aging more slowly?
No. Raising blood NAD+ is a biochemical result, not a health outcome. The Elhassan 2019 trial is the clearest illustration: NAD+ metabolites in muscle rose measurably while mitochondrial function did not change. Blood NAD+ is currently a marker that responds well to supplementation, not a validated measure of how fast you are aging.
Do NAD+ precursors show up on a biological age test?
Not directly. Epigenetic clocks read DNA methylation patterns, and no published trial has shown that NR or NMN moves a validated methylation clock. Any provider claiming their NAD+ product lowers biological age is describing a mechanism, not a measured result on their own test.
Are there safety concerns at trial doses?
Human trials of both compounds up to about 1,000 mg per day have generally reported tolerability similar to placebo over weeks to months, with mild gastrointestinal effects most commonly noted. Those trials were short, and long-term data in healthy adults is limited. Anyone with a cancer history should raise NAD+ supplementation with an oncologist specifically, because NAD+ metabolism is active in tumour biology and the direction of effect is not settled.
What should I measure if I take one of these?
There is no routine clinical NAD+ blood test with established reference ranges, so most people cannot track the thing the supplement targets. That is a real limitation worth knowing before you spend. Standard markers that respond to metabolic change, such as fasting insulin, HbA1c and hsCRP, tell you more about whether anything downstream shifted.